Loading stock data…
Novavax, Inc. (NVAX)
$9.42+0.06 (+0.64%)
After Hours$9.33-0.09 (-0.96%)· Last close Jun 30
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novavax, Inc. in the Healthcare sector is trading at $9.42 with a market capitalization of $1.7B. Wall Street consensus targets $14.11 (9 analysts), implying a +49.8% move over the next 12 months. The stock is currently 21% below its 52-week high of $11.97, remaining 10.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +49.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $139.51M↓ | $147.14M↑ | $70.44M↓ | $239.24M↓ | $666.65M |
| Gross Profit | $108.82M↓ | $125.03M↑ | $48.95M↓ | $223.91M↓ | $652.54M |
| Operating Income | -$15.43M↓ | $15.04M↑ | -$80.98M↓ | $101.07M↓ | $515.51M |
| Net Income | -$9.49M↓ | $17.53M↑ | -$202.38M↓ | $106.51M↓ | $518.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-1...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
60.68%
Volume
Today's trading volume
3.97M
Recent News
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Novavax (NVAX) stood at $8.9, denoting a -1.17% move from the preceding trading day.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Novavax (NVAX) closed the most recent trading day at $9.13, moving 3.89% from the previous trading session.
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is ... Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novavax (NASDAQ:NVAX) and its peers.